Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Return on Sales (2019 - 2025)

Revolution Medicines has reported Return on Sales over the past 7 years, most recently at 29.77% for Q4 2025.

  • Quarterly results put Return on Sales at 29.77% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 1363.01% (changed N/A YoY), and the annual figure for FY2023 was 38.02%, down 3097.0%.
  • Return on Sales for Q4 2025 was 29.77% at Revolution Medicines, down from 26.71% in the prior quarter.
  • Over the last five years, Return on Sales for RVMD hit a ceiling of 26.71% in Q3 2025 and a floor of 769.42% in Q3 2024.
  • Median Return on Sales over the past 5 years was 12.68% (2023), compared with a mean of 115.15%.
  • Biggest five-year swings in Return on Sales: tumbled -75674bps in 2024 and later soared 79613bps in 2025.
  • Revolution Medicines' Return on Sales stood at 5.57% in 2021, then surged by 33bps to 3.71% in 2022, then plummeted by -5902bps to 222.89% in 2023, then plummeted by -245bps to 769.42% in 2024, then surged by 96bps to 29.77% in 2025.
  • The last three reported values for Return on Sales were 29.77% (Q4 2025), 26.71% (Q3 2025), and 769.42% (Q3 2024) per Business Quant data.